[1]. Jian Zhou,Hui-Chuan Sun,Zheng Wang,Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition), Liver Cancer 2018;7:235–260
[2]. Jia-Zhou Ye, Yan-Yan Wang. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update,oncotarget/ Oncotarget, 2017, Vol. 8, (No. 54), pp: 93258-93278
[3] Gianelli G, Pierri F, Trerotoli P, et al. Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A restrospective clinical study of 150 cases. Hepatol Res, 2002,24:50-59.
[4] Kumada K, Ozawa K, Okamoto R ets. Hepatic resection for advanced hepatocellular carcinoma with removal of portal vein tumor thrombi. Surgery. 1990.180(5):821-7.
[5] Hu L, Xue F, A long-term follow-up and comprehensive observation of risk and prognosis factors of recurrence and survival after resection of hepatocellular carcinoma. Cell Biochem Biophys. 2014 Jul;69(3):421-31.
[6] Shu-You Peng, Better surgical treatment method for hepatcelluar carcinoma with portal vein tumor thrombus, World J Gastroenterol. 2018 October 28;24(40):4527-4535.
[7] Jiang-feng Xu, Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus: a novel classification, World Journal of Surgical Oncology. 2015,13:86.
[8] Zheng JS, Long J, Sun B, et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: Extending the indication for ablation?. Clin Radiol, 2014, 69(6):e253–63
[9] Lu ZH, Shen F, Yan ZL, et al. Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation. J Cancer Res Clin Oncol, 2009, 135(6):783–789
[10] Masaharu Hata, Koichi Tokuuye, Shinji Sugahara, et al. Proton Beam Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cancer 2005,104:794-801.
[11] Kudo M, Matsui O, Izumi N, et al. Liver Cancer Study Group on Japan. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 updated by the liver Cancer Study Group of Japan. Liver Cancer. 2014;3(3-4):458-468.
[12] He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953-960.
[13] Qin S, Bai Y, Lim Y, et al. Ramonized, multicenter, open-label study of oxaliplatn plus fluorouracil/leucovorin versus doxorubicin a palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2019;31(28):3501-3508.
[14] Yeo W, Mok TS, Zee B, et al. A randomized phase iii study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97(20):1532-1538.
[15] Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002:95(3):588-595.
[16] Park JY, Ahn SH, Yoon YJ, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced heapatocellular carcinoma. Cancer. 2007; 110(1):129-137.
[17] Patt YZ, Charnsangvej C, Yoffe b, et al. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicicn, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection of drug toxicity and patient survival. J Clin Oncol. 1994;12(6):1204-1211.
[18] Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology, 1994;106:1618-1624.
[19] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
[20] Stephen L Chan, Charing CN Chong, Anthony WH Chan, et al. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World Journal of Gastroenterology, 2016;22(32):7289-7300.
[21] Emma B. Holliday, Randa Tao, Zachary Brownlee, et al. Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thombus. Clinical and Translation Radiation Oncology, 2017;4:39-45.
[22] Calvo FA, Meirino RM, Orecchia R. Intraoperative radiation therapy first part: rationale and techniques. Crit Rev Oncol Hematol. 2006;59:106-15.
[23] Eaton DJ. Quality assurance and independent dosimetry for an intraoperative x-ray device. Med Phys. 2012;39:6908-20.
[24]. Eaton DJ, Duck S. Dosimetry measurements with an intra-operative x-ray device. Phys Med Biol. 2010;55:N359-69.
[25]. Eaton DJ, Gonzalez R, Duck S, Keshtgar M. Radiation protection for an intra-operative X-ray device. Br J Radiol. 2011;84:1034-9.
[26]. Ebert MA, Asad AH, Siddiqui SA. Suitability of radiochromic films for dosimetry of very-low energy X-rays. J Appl Clin Med Phys. 2009;10: 2957.
[27] Valentini V, Calvo F, Reni M, Krempien R, Sedlmayer F, Buchler MW, et al. Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol. 2009;91:54-9.
[28] He MK, Zou RH, Li QJ, et al. Phase ii study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carciniomar with major portal vein thrombosis. Cardiovasc Intervent Radiol. 2018;41(5):734-743.